In the past 50 years, only one new tuberculosis drug has come on to the market, yet many more active substances are urgently needed.
Current treatments increasingly fail due to multidrug-resistant pathogens. ETH researchers have now applied to patent a novel approach for developing new tuberculosis drugs.
Consumption was one of the worst known diseases of the 18th century. Thanks to medical advances, the number of deaths from this lung disease â which is today known as tuberculosis â